Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- DPJ Calls For Net Increases in Medical Fees
January 4, 2010
- No Serious Concern about Safety of New-Type Flu Vaccines Made in Japan
January 4, 2010
- Quintiles to Offer More Risk-Sharing Business Models: Dr Winstanly
January 4, 2010
- 78.1% of Consumers against Exclusion of Poultices from Insurance Coverage: Survey
January 4, 2010
- Eisai Confident of Overcoming Aricept Patent Expiration: Mr Naito
January 4, 2010
- Keidanren Lists Healthcare, Drugs as Major Growth Fields
January 4, 2010
- Multaq Approved by EC for AF: sanofi-aventis
January 4, 2010
- NOF Licenses Polymer-Micelle Carrier Technology from NanoCarrier
January 4, 2010
- H1N1 Vaccine Arepanrix Prequalified by WHO: GSK
January 4, 2010
- Kyowa Hakko Bio to Transfer Domestic Livestock, Aquaculture Business to ASKA
January 4, 2010
- Shionogi: Locusta for Hypercholesterolemia
January 4, 2010
- Pharmacies Don't Need Wholesalers’Information Services: Mr Fukai of Nihon Chouzai
January 4, 2010
- Mail-Order Drug Market Down 22.7% in 2009
January 4, 2010
- Teva-Kowa Aims at 10% Share in Generics Market
January 4, 2010
- Bendamustine's Efficacy Confirmed for Low-Grade NHL: SymBio
January 4, 2010
- JCR Allies with GSK for Biosimilars
January 4, 2010
- GSK Considers Disclosing All Payments to Med Institutions
January 4, 2010
- Ms Bresch Calls For Generics Promotion Measures Easier for General Consumers to Understand
January 4, 2010
- TAK-085 Enters PIII for Hypertriglyceridemia in Japan: Takeda
January 4, 2010
- Hospital Market Key to Success of Prasugrel: Mr Shoda
December 21, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…